Martell Christopher 4/A
4/A · Candel Therapeutics, Inc. · Filed Feb 17, 2023
Insider Transaction Report
Form 4/AAmended
Martell Christopher
Director
Transactions
- Purchase
Common Stock
2022-12-08$1.68/sh+3,050$5,124→ 128,050 total(indirect: By LLC) - Purchase
Common Stock
2022-12-09$1.92/sh+23,950$45,984→ 152,000 total(indirect: By LLC)
Holdings
- 283,514(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.55 to $1.80. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.88 to $1.98. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
- [F4]Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.